Assessing the Effect of the Silver Dressing on Surgical Site Infections in Adult Patients Post Cardiac Surgery: a Single Center Randomized Control Trial
Launched by KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTER · May 29, 2025
Trial Information
Current as of November 14, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This trial is testing whether using a silver dressing on chest wounds after adult cardiac surgery reduces surgical site infections (SSIs) within 30 days after the operation, compared with standard foam dressings. It’s a randomized, open-label study (participants and care teams will know which dressing is used) being conducted at King Faisal Specialist Hospital & Research Center in Jeddah, Saudi Arabia. About 145 adults are expected to enroll, and patients will be followed in the ICU, CCU, or cardiology telemetry units to see whether the wound becomes infected.
Eligibility and participation are straightforward: adults 18 or older who are scheduled for cardiac surgery requiring a sternotomy can join, provided they do not have an existing infection and are not on systemic antibiotics beyond perioperative prophylaxis. Exclusions include redo surgeries, open-chest status, emergency procedures, use of ECMO, very heavy bleeding, or an allergy to silver dressings. If enrolled, participants are randomly assigned to receive either the silver dressing or the standard dressing and will be observed for 30 days post-surgery using a simple checklist. The study aims to improve wound care in heart surgery, with completion anticipated by the end of 2026; no personal data will be shared publicly.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients 18 years of age and older are scheduled for cardiac surgery requiring a sternotomy incision.
- • Exclusion criteria Presence of a concurrent infection and any systemic antibiotic other than those used for perioperative prophylaxis.
- • Patients who died without an infection within thirty days following surgery. Patients who had undergone another procedure through the same incision(s) within a year after enrollment in this study.
- • Patients who are a redo- such as needing debridement or an infection. Patients who have an open chest Patients on ECHMO Patients excessively bleeding Patients who require the surgery as an emergency Patients with a known allergy to silver dressings
- • -
About King Faisal Specialist Hospital & Research Center
King Faisal Specialist Hospital & Research Center (KFSH&RC) is a leading medical institution in Saudi Arabia, dedicated to providing advanced healthcare services, conducting pioneering research, and training healthcare professionals. Founded in 1975, KFSH&RC specializes in comprehensive patient care across various disciplines, including oncology, organ transplantation, and genetics. The center is recognized for its commitment to clinical excellence and innovation, actively participating in clinical trials to enhance treatment options and improve patient outcomes. With state-of-the-art facilities and a multidisciplinary team of experts, KFSH&RC plays a pivotal role in advancing medical knowledge and improving healthcare standards in the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jeddah, Saudi Arabia
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported